Nrx pharmaceuticals, inc. announces pricing of $1.5 million underwritten public offering of common stock together with investor commitment for additional $1 million

Radnor, pa. , feb. 27, 2024 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp), ("nrx pharmaceuticals" or the "company"),  a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten public offering of  shares of its common stock (or pre-funded warrants in lieu thereof) at a public offering price of $0.30 per share, for aggregate gross proceeds of approximately $1,500,000 million, prior to deducting underwriting discounts and other offering expenses.
NRXP Ratings Summary
NRXP Quant Ranking